EPISODE · Feb 24, 2026 · 35 MIN
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
from BioCentury This Week · host BioCentury
Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the deal does for the Foster City, Calif.-based biotech’s pipeline.The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week’s PhRMA Forum, which focused on China and the Trump administration’s most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA’s about-face on the recent vaccine application from Moderna.View full story: https://www.biocentury.com/article/658516#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA00:00 - Introduction02:34 - Gilead's Arcellx Buy11:14 - ctDNA Surrogate Endpoints21:59 - PhRMA Forum Takeaways29:19 - FDA Moderna U-turnTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
What this episode covers
Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the deal does for the Foster City, Calif.-based biotech’s pipeline. The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week’s PhRMA Forum, which foc...
NOW PLAYING
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m